IRWD logo

IRONWOOD PHARMACEUTICALS INC

IRWDNASDAQ
🏆 #2748 by market capEarnings Oct 29US Equity
$343.16▼ $1.65 (−0.48%)
Simulated price
🔔
Track IRWD
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.5%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$685M
Small Cap
📈Revenue Growth (YoY)
-15.7%
Declining
📊Gross Margin
99.8%
High
💵FCF Margin
47.7%
Strong
⚖️P/S Ratio
1.8x
Cheap
Otter Score
76
Good
No chart data available for IRWD.

Trading Snapshot

Day Range
$341.72 – $344.54
52-Week Range
$1.29 – $5.78
Volume
$5.89B
Avg Volume
$6.04B
Shares Outstanding
164.6M
Next Earnings
Dec 8, 2026

Fundamentals Snapshot

Annual Revenue
$296M
Last Q Revenue
$113M
P/E Ratio
5.2
P/S Ratio
1.8x
EPS (TTM)
$0.78
Dividend Yield
0.00%
Dilution (1yr)
+10.8%

Why Investors Own IRWD

  • ✓High-growth profile — revenue up +36.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 75% gross margin and 14% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

IRWD logo

IRONWOOD PHARMACEUTICALS INC

IRWD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$296M▼ −15.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +2.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$119M▲ +27.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$127M▲ +22.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
177.8M▲ +10.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$382M▲ +$129M YoY
StockOtter · stockotter.space

About IRONWOOD PHARMACEUTICALS INC

Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100

Analyst Price Target

ⓘ
Average Target
$406.38
▲ +18.4% Upside
High Target$493.33
Low Target$372.60
Based on 24 analysts

Latest News & Updates

🚀
Barron’s·2h ago

IRONWOOD PHARMACEUTICALS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift IRWD price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

IRONWOOD PHARMACEUTICALS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.